Insight Into the Latest Findings in Migraine

Slides:



Advertisements
Similar presentations
1997 NIH Consensus Myofascial pain Osteoarthritis Low back pain Headache Menstrual cramps Tennis elbow Fibromyalgia Carpal tunnel syndrome Addiction Stroke.
Advertisements

Meredith Tilley, PharmD Candidate Cone Health Family Medicine
MOnoclonal antibodies and potential applications in migraine
How the Latest Data in MDD Can Guide Treatment Decisions:
Methods Subjects: yo w migraine wwo aura (defined by ICHD3beta) for at least 1yr ≥4 and
CGRP THERAPEUTIC MONOCLONAL ANTIBODIES
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons From Clinical Trials.
An Endocrinology Clinic in Dyslipidemia
Updates in the Clinical Science of CGRP Antagonism for the Treatment of Migraine.
PCP Perspectives Pathophysiologic Principles in the Management of Hyperkalemia.
At The Cutting Edge of Developments in the Management of Hyperkalemia
Chronic Rhinosinusitis
Migraine Prevention Therapy: Avoiding Overuse of Medications
Advances in CKD.
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
PCP Perspectives Clinical Considerations in Hyperkalemia
Case Challenges in Chronic Migraine
Please consider these data to be preliminary until they have been published in peer-reviewed journals.
New Treatments for CTEPH
What Has Been Tried and What Is True?
The Vicious Cycle of Chronic Migraine How Can the Physician Help?
Updates in Migraine From a 2018 American Headache Meeting
Managing CINV and Cachexia
Translating Atopic Dermatitis
Diagnostic and Management Challenges in Patients With Chronic Migraine
Results w the CI.
Demystifying the Science of Monoclonal Antibodies in Migraine
Poor Response to Initial Therapy for Migraine
Extending Treatment for Thrombosis: What’s the Right Choice?
Battling Constipation
Current and Future Perspectives on Migraine Prevention Therapy
Extraordinary Cases of VTE Prevention in Patients With Cancer
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Hidden in Plain Sight: Disrupted Sleep in Patients With Pain
New Data on Emerging Treatments for Psoriasis
Improving Outcomes in Psoriatic Arthritis
Breaking New Ground With Migraine Prevention Therapies
Duration of Dual Antiplatelet Therapy Post-ACS: Lessons from Clinical Trials.
Updates in Seizure Management
Getting to Grips With the Science of CGRP and Migraine
Battling the Flu: Latest Advances in the Influenza Treatment Arsenal
Scientific Update.
Defining the Clinical Value of Endpoints Used in Migraine Trials
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Are We Making Progress in the Management of Huntington Disease?
Managing Pulmonary Embolism Posthospital Discharge
“ Einstein had a lot more astrocytes than the average human brain 6.
Patient and Clinician Perspectives on Preventive Therapy for Migraine
Challenges in LA SCCHN.
Elevated Admission Plasma Glucose Following ACS
Peanut Allergy Immunotherapy
An Unmet Need.
Peanut Allergy Immunotherapy
The Biologic Basis of Migraine
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Real-World Evidence.
A Closer Look.
Migraine Therapeutics in Development
Patient and Clinician Perspectives on Preventive Therapy for Migraine
The Glutamate Pathway.
Diagnostic Criteria Migraine Without Aura
What's New in Oral Combination Therapy for Type 2 Diabetes?
Monoclonal Antibodies in Migraine Prevention: What the Primary Care Physician Needs to Know.
A New Era in Migraine Prevention
Risk Factors for Migraine Chronification
Meet the JAKs.
Antithrombotic Therapy in AF Patients Undergoing PCI
Psoriatic Arthritis.
2019 MPhA Annual Networking Learning Event & MTM Symposium
Therapy of the Acute Migraine Attack. Therapy of the Migraine Attack Criteria for efficacy Pain free after 2 hrs Improvement of headache from severe.
Presentation transcript:

Insight Into the Latest Findings in Migraine

Epidemiology of Migraine: Sex Differences From CaMEO Study

CaMEO Study: Sex Differences in Consulting Behavior

Validation of the MPFID

Role of the Hippocampus in Migraine

CSD and Prolonged Neuronal Activation and Sensitization

CSD and Migraine Headache

Brain Trauma and Increased Cortical Network Activity in a Migraine Mutant Mouse

Green Light Less Photoallodynic in Migraine Than Blue, Amber, or Red

OnabotulinumtoxinA in Prevention of Chronic Migraine: COMPEL Study

CGRP

Phase 1 Study of Erenumab (AMG334) and Sumatriptan on BP

Hepatic Safety of Galcanezumab (LY2951742): Pooled Analysis of Three Phase 2 Studies

Efficacy of Erenumab in Episodic Migraine: Phase 3 STRIVE Trial

Reduction in Migraine Days and Acute Medication Use With Erenumab: STRIVE

Improvement in Activity Scores With Erenumab: STRIVE

Efficacy of Erenumab in Episodic Migraine: Phase 3 ARISE Trial Primary Endpoint

Reduction in Migraine Days With Erenumab in Chronic Migraine

Safety of Erenumab in Episodic Migraine: Phase 3 STRIVE Trial

Efficacy of Eptinezumab (ALD403) in Chronic Migraine: Phase 2 Study

sTMS in Reduction of Migraine Headache: ESPOUSE Study

Zolmitriptan Nasal Spray in Acute Treatment of Adolescents With Migraine

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)